Reagents and kits for determination of fetal fibronectin in a vaginal sample

• US 5,281,522 A
• Filed: 12/14/1990
• Issued: 01/25/1994
• Est. Priority Date: 09/15/1988
• Status: Expired due to Term

• Current Assignee: Cytyc Corporation (Hologic Incorporated)
• Original Assignee: Cytyc Prenatal Products Corp. (Hologic Incorporated)
• Inventors: Senyei, Andrew E., Teng, Nelson N. H.
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US07/628,282
• Time in Patent Office: 1,138 Days
• Field of Search: 436/547, 436/536, 436/518, 436/528, 436/543, 435/7.9
• US Class Current: 435/7.9
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: G01N 2800/36 Gynecology or obstetrics
• CPC Class Codes: G01N 2800/368 Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
• CPC Class Codes: G01N 33/57476 involving oncofetal proteins
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/689 related to pregnancy or the gonads
• CPC Class Codes: G01N 33/76 Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Abstract

This invention relates to methods, reagents and kits for detection of normal or ectopic pregnancy, the termination of pregnancy, or increased risk of preterm labor and rupture of membranes. Each embodiment involves sampling from the vaginal cavity, and determining the presence or absence of a specific analyte in the test sample. Sandwich or competition assay procedures can be used. Reagents and reagent kits for the above assays are included. The kit contains anti-(fetal fibronectin) antibody and an anti-fibronectin antibody.

Claims

1. A kit for detecting fetal fibronectin in a vaginal sample comprising:

a. an anti-(fetal fibronectin) antibody;

b. an anti-fibronectin antibody,

wherein either said anti-(fetal fibronectin) antibody or said anti-fibronectin antibody is adhered to an insoluble support; and

c. a device selected from the group consisting of a vaginal sample collection device, a vaginal sample filtration device, and a vessel containing a vaginal sample diluent.

2. The kit of claim 1 wherein said anti-(fetal fibronectin) antibody is a monoclonal antibody.

3. The kit of claim 2 wherein said anti-(fetal fibronectin) antibody is FDC-6.

4. The kit of claim 1 wherein said anti-fibronectin antibody is a polyclonal antibody.

5. The kit of claim 4 wherein said anti-fibronectin antibody is labeled.

6. The kit of claim 5 wherein said label is an enzyme.

7. The kit of claim 6 wherein said enzyme is alkaline phosphatase.

8. The kit of claim 7 wherein said kit additionally comprises enzyme substrate.

9. The kit of claim 8 wherein said enzyme substrate is phenolphthalein monophosphate.

10. The kit of claim 5 wherein said label is colloidal gold.

11. The kit of claim 1 wherein said insoluble support comprises a microtiter plate or a strip of wells of a microtiter plate.

12. The kit of claim 11 wherein said kit additionally comprises a microtiter plate cover.

13. The kit of claim 11 wherein said kit includes a strip of wells of a microtiter plate and additionally comprises a holder for said strip.

14. The kit of claim 1 wherein said kit additionally comprises a positive, control.

15. The kit of claim 14 wherein said positive control is amniotic fluid of a known fetal fibronectin concentration.

16. The kit of claim 15 wherein said fetal fibronectin concentration is from about 10 to about 100 ng/mL.

17. The kit of claim 16 wherein said amniotic fluid is diluted in 0.05M Tris buffer pH 7.4, 1% bovine serum albumin, 0.15M sodium chloride, 0.02% Sodium Azide, 5 mM ethylenediamine tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, and 500 Kallikrein Units/ml of Aprotinin.

18. The kit of claim 1 wherein said kit additionally comprises a negative control.

19. The kit of claim 18 wherein said negative control is 0.05M Tris buffer pH 7.4, 1% bovine serum albumin, 0.15M sodium chloride, 0.02% Sodium Azide, 5 mM ethylenediamine tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, and 500 Kallikrein Units/ml of Aprotinin.

20. The kit of claim 1 wherein said kit additionally comprises at least one sample filtering device.

21. The kit of claim 20 wherein said sample filtering device dispenses a predetermined volume of filtered sample.

22. The kit of claim 1 wherein said kit additionally comprises a rinse buffer.

23. The kit of claim 22 wherein said rinse buffer is 0.02M Tris, 0.08M sodium chloride and 0.05% Tween-20.

24. The kit of claim 23 wherein said rinse buffer additionally comprises sodium azide.

25. The kit of claim 23 wherein said rinse solution is packaged in concentrated form.

26. The kit of claim 1 wherein said unsoluble support is a membrane.

27. The kit of claim 26 wherein said membrane is nylon.

28. The kit of claim 26 wherein said membrane is placed over an absorbent layer.

29. The kit of claim 28 wherein a flow control layer is intermediate said membrane and said absorbent layer.

30. The kit of claim 26 wherein said kit additionally comprises a sample filtering device which contains labeled anti-fibronectin antibody.

31. The kit of claim 7 wherein the alkaline phosphatase-labeled anti-fibronectin antibody is in an enzyme conjugate buffer comprising 50 mM Tris, pH 7.2;

2% D-Sorbitol;

2% bovine serum albumin;

0.01% Tween-20;

1 mM MgCl₂ ;

0.1% ZnCl₂ ; and

optionally 0.1% sodium azide.

32. The kit of claim 9 wherein the phenolphthalein monophosphate is in an enzyme substrate solution containing 2-amino-2-methyl-1-propanol and MgCl₂.

33. The kit of claim 32 wherein said enzyme substrate solution comprises 1 mg/ml phenolphthalein monophosphate;

0.4M 2-amino-2-methyl-1-propanol, pH 10;

0.1 mM MgCl₂ ; and

, optionally 0.2% sodium azide.

34. The kit of claim 10 wherein the gold-labeled anti-fibronectin antibody conjugate is in a protein matrix in a conjugate buffer comprising 15 mM Tris;

0.1% Tween 20;

0.2% polyethylene glycol;

8% polyvinylpyrrolidine; and

, optionally 0.04% thimerosal.

35. The kit of claim 34 wherein the protein matrix comprises 2% bovine serum albumin.

36. The kit of claim 35 wherein said antibody conjugate is lyophilized.

37. The kit of claim 36 wherein said kit includes a conjugate reconstitution buffer.

38. The kit of claim 37 wherein said conjugate reconstitution buffer comprises 100 mM sodium acetate.

39. The kit of claim 1 wherein said device is a vaginal sample collection device.

40. The kit of claim 1 wherein said device comprises a swab.

41. The kit of claim 40 wherein said swab is a dacron swab.

42. A kit for detecting a fetal fibronectin in a vaginal sample comprising:

a. an anti-(fetal fibronectin) antibody adhered to a well of a microtiter plate;

b. an alkaline phosphatase-labeled anti-fibronectin antibody in an enzyme conjugate buffer comprising 50 mM Tris, pH 7.2;

2% D-Sorbitol;

2% bovine serum albumin;

0.01% Tween-20;

1 mM MgCl₂ ;

0.1% ZnCl₂ ; and

optionally 0.1% sodium azide;

c. phenolphthalein monophosphate is in a enzyme substrate solution comprising 1 mg/ml phenolphthalein monophosphate;

0.4M 2-amino-2-methyl-1-propanol, pH 10;

0.1 mM MgCl₂ ; and

, optionally 0.2% sodium azide; and

d. a device selected from the group consisting of a vaginal sample collection device, a vaginal sample filtration device, and a vessel containing a vaginal sample diluent.

43. The kit of claim 42 wherein the kit additionally contains a rinse buffer concentrate comprising 0.1M Tris, pH 7.4;

4.0M NaCl;

2.5% Tween-20; and

, optionally 1.0% sodium azide.

44. The kit of claim 42 wherein the kit additionally comprises a positive and a negative control.

45. A kit for detecting a fetal fibronectin in a test sample comprising:

a. an anti-(fetal fibronectin) antibody adhered to a nylon membrane, said membrane placed over an absorbent layer and having a flow control layer intermediate said membrane and said absorbent layer;

b. a lyophilized gold-labeled anti-fibronectin antibody conjugate comprising 15 mM Tris;

2% bovine serum albumin;

0.1% Tween 20;

0.2% polyethylene glycol;

8% polyvinylpyrrolidine; and

, optionally 0.04% thimerosal; and

c. a reconstitution buffer comprising 100 mM sodium acetate.

46. The kit of claim 45 wherein said membrane additionally includes a control region comprising membrane-affixed fibronectin.